Neurorehabilitation News

Continuous treatment with avalglucosidase alfa, or after a switch from alglucosidase alfa, maintained respiratory function and functional endurance in patients with late-onset Pompe disease, with no new safety concerns reported.

Adding once-daily opicapone 50 mg to carbidopa/levodopa therapy helped achieve and maintain plasma concentrations of levodopa in patients with Parkinson’s disease, according to research in Clinical Neuropharmacology.

In older adults with traumatic brain injury and acute subdural hematoma, early neurosurgical intervention resulted in the highest 30-day mortality rates, while delayed surgery yielded better outcomes.

Merck KGaA announced the FDA has paused the initiation of new patients on evobrutinib for relapsing-remitting MS, as well as those with less than 70 days exposure to the treatment in the United States.

Regenxbio Inc. announced that the FDA has granted fast track designation for RGX-202, a one-time gene therapy for treatment of Duchenne muscular dystrophy.

In adults with drug-refractory focal epilepsy, treatment with an implanted neurostimulation device was safe and associated with significant reduction in seizure frequency, according to a study published in JAMA Neurology.

Alzamend Neuro Inc. announced initiation of a phase 1/2a clinical trial for its proprietary immunotherapy vaccineALZN002 to treat mild to moderate dementia associated with Alzheimer’s disease.

Vico Therapeutics announced that the first patient has been dosed in a phase 1/2a study evaluating VO659, an investigational antisense oligonucleotide for Huntington’s disease and spinocerebellar ataxia types 1 and 3.

Speed of processing training reduced the risk for future falls over 10 years in high-risk older adults, while reasoning and memory training did not reduce the likelihood of future falls in this population, according to research.

Patients with fibromyalgia were at greater risk for pain-related exacerbations of opioid use disorder, according to a study published in Pain.